Clinical Trials

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06052306 2026-04-17

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

232 enrolled

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06402331 2026-04-08

AlphaBreak

110 enrolled

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06909825 2026-04-08

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

85 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT02044354 2026-04-01

CABA-DOC

Phase 3 Completed

195 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04853498 2026-03-31

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Phase 1 Terminated

192 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06193486 2026-03-31

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

30 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

162 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

12 enrolled

Phase 3 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05125016 2026-02-27

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Phase 1/2 Recruiting

370 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06533644 2026-02-27

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

70 enrolled

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04754191 2026-02-12

ENCORE

34 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

60 enrolled

Phase 3 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT06492122 2026-01-29

ProTACT

50 enrolled

Phase 3 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Phase 1/2 Enrolling by invitation

Metastatic Castration-resistant Prostate Cancer

NCT05570994 2026-01-08

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

50 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06866938 2026-01-06

ReaLuP

58 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06155084 2025-12-22

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Phase 1/2 Recruiting

84 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06228053 2025-12-22

SYNERGY-201

53 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06568562 2025-12-09

PRO-XL

32 enrolled

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05682443 2025-12-02

PRESERVE-006

148 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06029998 2025-11-28

BORXPTEN

22 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06100705 2025-11-04

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

26 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05613894 2025-10-31

CaboLu

33 enrolled

Phase EARLY_PHASE1 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05603559 2025-10-03

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

30 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04158245 2025-09-22

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Phase 2 Completed

9 enrolled 14 charts

Phase 1/2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07172126 2025-09-15

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

291 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05544227 2025-07-23

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

15 enrolled

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06383052 2025-05-21

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

30 enrolled

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

13 enrolled